Kexin Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kexin Peng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Wenghong Wong
Department of Dermatology Huashan Hospital, Shanghai Institute of Dermatology, Fudan University Shanghai China
2 shared publications- Zhenghua Zhang
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology , Shanghai
2 shared publications Jiewen Pan
Department of Dermatology Huashan Hospital, Shanghai Institute of Dermatology, Fudan University Shanghai China
1 shared publicationJing Luan
Department of Dermatology Huashan Hospital, Shanghai Institute of Dermatology, Fudan University Shanghai China
1 shared publicationKaihang Yang
Department of Dermatology Huashan Hospital, Shanghai Institute of Dermatology, Fudan University Shanghai China
1 shared publicationKexiang Yan
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology , Shanghai , People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 25 September 2024
- Published by Wiley in Skin Research and Technology
- Vol. 30 (9) , e70076
Establishment of a Mouse Model for Porokeratosis Due to Mevalonate Diphosphate Decarboxylase Deficiency
Introduction: Porokeratosis (PK) is an autoinflammatory keratinization disease (AIKD) characterized by circular or annular skin lesions with a hyperkeratotic rim, pathologically shown as the cornoid lamella. Four genes that cause PK are associated with the mevalonate (MV) pathway. In Chinese PK patients, mevalonate diphosphate decarboxylase ( MVD ) is the most common causative gene. The lack of an animal model has greatly limited research on PK pathogenesis. Materials and Methods: In this research, we constructed K14‐CreER T2 ‐ Mvd fl/fl mice using the Cre‐LoxP system to create a mouse model for in‐depth studies of PK. The Epidermal Mvd gene was knocked out by intraperitoneal injection of Tamoxifen (TAM). Pathology, immunohistochemistry, RNA‐seq, and Western Blot analysis were performed. Results: Skin lesions appeared following Mvd deficiency, and pathological examination revealed the characteristic cornoid lamella, as well as cutaneous inflammation. Furthermore, we observed elevated levels of IL‐17A and IL‐1β, and a decreased Loricrin level in epidermal Mvd‐deficient mice. Compared with the wild‐type (WT) group, Mvd deficiency activated the expression of lipid metabolism‐related proteins. Conclusion: We developed the first mouse model for PK research, enabling further studies on disease development and treatment approaches.
- 25 September 2024
- Published by Wiley in Skin Research and Technology
- Vol. 30 (9) , e70076
Open AccessEstablishment of a Mouse Model for Porokeratosis Due to Mevalonate Diphosphate Decarboxylase Deficiency
Introduction: Porokeratosis (PK) is an autoinflammatory keratinization disease (AIKD) characterized by circular or annular skin lesions with a hyperkeratotic rim, pathologically shown as the cornoid lamella. Four genes that cause PK are associated with the mevalonate (MV) pathway. In Chinese PK patients, mevalonate diphosphate decarboxylase ( MVD ) is the most common causative gene. The lack of an animal model has greatly limited research on PK pathogenesis. Materials and Methods: In this research, we constructed K14‐CreER T2 ‐ Mvd fl/fl mice using the Cre‐LoxP system to create a mouse model for in‐depth studies of PK. The Epidermal Mvd gene was knocked out by intraperitoneal injection of Tamoxifen (TAM). Pathology, immunohistochemistry, RNA‐seq, and Western Blot analysis were performed. Results: Skin lesions appeared following Mvd deficiency, and pathological examination revealed the characteristic cornoid lamella, as well as cutaneous inflammation. Furthermore, we observed elevated levels of IL‐17A and IL‐1β, and a decreased Loricrin level in epidermal Mvd‐deficient mice. Compared with the wild‐type (WT) group, Mvd deficiency activated the expression of lipid metabolism‐related proteins. Conclusion: We developed the first mouse model for PK research, enabling further studies on disease development and treatment approaches.
- 29 April 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (10) , 1239-1241
Effective treatment of solar facial porokeratosis in one patient with topical atorvastatin/cholesterol cream
We report a rare case of solar facial porokeratosis (SFP) treated topically with atorvastatin/cholesterol or cholesterol alone for 48 weeks. The patient reported no obvious skin irritation and was delighted with the outcome. This study supported the effectiveness of a pathogenesis-directed treatment for SFP. Moreover, we point out that topical statins combined with cholesterol might have a long-term benefit in the treatment of SFP.
- 29 April 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (10) , 1239-1241
Effective treatment of solar facial porokeratosis in one patient with topical atorvastatin/cholesterol cream
We report a rare case of solar facial porokeratosis (SFP) treated topically with atorvastatin/cholesterol or cholesterol alone for 48 weeks. The patient reported no obvious skin irritation and was delighted with the outcome. This study supported the effectiveness of a pathogenesis-directed treatment for SFP. Moreover, we point out that topical statins combined with cholesterol might have a long-term benefit in the treatment of SFP.